Compare Abeona Therapeutics Inc (ABEO) vs Avient Corporation (AVNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Avient Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Avient Corporation trades at $35.52 (market cap $3.49B). The key difference: Avient Corporation is far larger — about 9.3× Abeona Therapeutics Inc's market cap, and Avient Corporation pays a 2.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AVNT | |
|---|---|---|
Market Cap | $373.32M | $3.49B |
Sector | Health | Technology |
52-Week High | $7.23 | $43.28 |
52-Week Low | $4.17 | $27.48 |
Enterprise Value | $228.22M | $4.99B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Avient Corporation (AVNT) trades at $38.89, up 4.23% today, reflecting positive momentum. The stock exhibits a bullish technical outlook with strong analyst support (12 Buy, 8 Hold, 0 Sell). Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $0.83 surpassing the $0.81 forecast. The company maintains solid fundamentals, including a P/E of 22.58 and net income margin of 4.81%, while recent news highlights innovation in non-PFAS barrier technology and new dielectric thermoplastics.
The outlook for AVNT is positive, driven by earnings outperformance, strategic product launches, and favorable analyst sentiment. Key opportunities include growth in 5G/6G materials and sustainable packaging solutions. Risks involve exposure to economic cycles impacting demand and competitive pressures in the specialty materials sector. Investors should weigh strong fundamentals against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
